KMDA लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 01:30):

Stats
आज की मात्रा	34 789.00
औसत मात्रा	21 083.00
बाजार मूल्य	330.48M
EPS	$0 ( 2024-03-06 )
अगली कमाई की तारीख	( $0.0600 ) 2024-05-08
Last Dividend	$0.00600 ( 2013-06-13 )
Next Dividend	$0 ( N/A )
P/E	38.33
ATR14	$0.0170 (0.30%)

मात्रा सहसंबंध

लंबा: -0.23 (neutral)

छोटा: 0.59 (weak)

Signal:(55.552) Neutral

Kamada Ltd सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
GAINL	0.895
SHC	0.891
RMRM	0.88
HDSN	0.877
SHLS	0.868
EA	0.846
LPRO	0.843
GDYN	0.837
EYEN	0.836
DMRC	0.833

10 सबसे अधिक नकारात्मक सहसंबंध
SIEB	-0.876
HZNP	-0.867
CURI	-0.842
PPTA	-0.84
LWAY	-0.837
GALT	-0.836
SCTL	-0.829
VFF	-0.821
XLO	-0.82
IGLD	-0.819

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Kamada Ltd सहसंबंध - मुद्रा/वस्त्र

0.31
( neutral )

0.45
( neutral )

0.00
( neutral )

-0.37
( neutral )

-0.59
( weak negative )

Kamada Ltd वित्तीय

Annual	2023
राजस्व:	$144.76M
सकल लाभ:	$52.59M (36.33 %)
EPS:	$0.170

FY	2023
राजस्व:	$144.76M
सकल लाभ:	$52.59M (36.33 %)
EPS:	$0.170

FY	2022
राजस्व:	$129.34M
सकल लाभ:	$46.70M (36.11 %)
EPS:	$-0.0518

FY	2021
राजस्व:	$103.64M
सकल लाभ:	$30.33M (29.26 %)
EPS:	$-0.0500

Financial Reports:

No articles found.

Kamada Ltd Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Kamada Ltd Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.03 - good (90.33%) | Divividend Growth Potential Score: 2.32 - No dividend growth expected in the near future

Information

First Dividend	$0.00600	2013-06-13
Last Dividend	$0.00600	2013-06-13
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.00600	--
Avg. Dividend % Per Year	0.00%	--
Score	1.71	--
Div. Sustainability Score	9.03
Div.Growth Potential Score	2.32
Div. Directional Score	5.68	--

Next Divdend (Est)
(2024-05-05)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

1.71

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2013	$0.00600	0.06%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0574	1.500	8.85	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0235	1.200	9.22	10.00	[0 - 0.3]
returnOnEquityTTM	0.0398	1.500	-0.669	-1.003	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.43	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.554	0.800	5.56	4.45	[0.8 - 2.5]
cashRatioTTM	1.122	1.500	4.88	7.32	[0.2 - 2]
debtRatioTTM	0.0250	-1.500	9.58	-10.00	[0 - 0.6]
interestCoverageTTM	6.53	1.000	8.69	8.69	[3 - 30]
operatingCashFlowPerShareTTM	0.0760	2.00	9.97	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.0278	2.00	-0.0139	-0.0278	[0 - 20]
debtEquityRatioTTM	0.0364	-1.500	9.85	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.389	1.000	6.84	6.84	[0.2 - 0.8]
operatingProfitMarginTTM	0.0587	1.000	-0.827	-0.827	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.496	1.000	8.36	8.36	[0.2 - 2]
assetTurnoverTTM	0.410	0.800	-0.598	-0.478	[0.5 - 2]
Total Score				9.03

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	39.90	1.000	6.07	0	[1 - 100]
returnOnEquityTTM	0.0398	2.50	-0.430	-1.003	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0278	2.00	-0.00928	-0.0278	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0760	2.00	9.97	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.706	1.500	8.62	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0302	1.000	-1.744	0	[0.1 - 0.5]
Total Score				2.32

Kamada Ltd

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

के लिए वास्तविक समय के अद्यतन Kamada Ltd [KMDA]

Upcoming Earnings Alert

Kamada Ltd Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)